neutralizing antibody as35 human igg1  (ACROBiosystems)

Journal: Nature communications

Article Title: De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination.

doi: 10.1038/s41467-024-53105-8

Figure Lengend Snippet: Fig. 1 | Schematic overview of the sequencing pipeline. A Overview analysis of human antibody repertoires from antigen-specific IgG and peripheral blood. Two different types of samples were taken and analyzed; the bottom branch is the procedure of generating a reference database of immunoglobulin V-region by next- generation sequencing (NGS) of the immunized individual’s B cell repertoire. The branch above describes the analysis of soluble serum IgG. This comparison and functional characterization of the two antibody repertoires provide a different perspective on studying humoral response. This process involves the purification and the proteomic analysis of affinity-purified serum antibody (MS-based de novo, top) alongside VH: VL pairing and NGS of peripheral B cell V gene repertoires (BCR-

Article Snippet: For the positive controls, we used the following antibodies: Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 AS35 (Acro Biosystems, clone AS35, lot no. S35-21CHF1-ZS) (see Fig. 4B, C), and Anti-Spike RBD Neutralizing Antibody, S1N-M122 (Clone AM122) from Acro Biosystems (see Fig. 4D).

Techniques: Sequencing, Next-Generation Sequencing, Comparison, Functional Assay

Journal: Cell reports. Medicine

Article Title: Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.

doi: 10.1016/j.xcrm.2023.101134

Figure Lengend Snippet: Figure 3. SARS-CoV-2 IgG and neutralizing antibody responses (A and B) Serum IgG titers against wild-type SARS- CoV-2 RBD protein (A) and pseudovirus neutralizing antibody titers (ID50) against SARS-CoV-2 variants (B) for non-elderly (left side) and elderly (right side) participants (n = 10 per dose group, and n = 6 for the placebo group). Participants received one injection of VLPCOV-01 (0.3, 1.0, or 3.0 mg), 30 mg BNT162b2, or placebo on day 1 (week 0). Logarithmic values are reported as geometric mean titers for serum IgG and neutralizing antibody against pseudovirus. Bars indicate 95% CIs. (C) The correlation between serum neutralizing antibody titers against pseudovirus Wuhan (wild type) and IgG antibody titers against SARS-CoV-2 RBD protein following booster vaccination. Pearson’s product-moment correlation coefficient and p value were calculated following log trans- formation of source data (r = 0.950, p < 0.001).

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies Mouse anti-human CD154-FITC (clone: TRAP1) BD Biosciences cat# 555699; RRID: AB_396049 Mouse anti-human CD3-BUV615 (clone: SP34-2) BD Biosciences cat# 751249; RRID: AB_2875266 Mouse anti-human CD4-PE-Cy5.5 (clone: S3.5) Thermo Ficher Scientific cat# MHCD0418; RRID: AB_10376013 Mouse anti-human CD8-BUV563 (clone: RPA-T8) BD Biosciences cat# 612914; RRID: AB_2870200 Mouse anti-human CD27-PE-Cy5 (clone: 1A4CD27) Beckman coulter cat# 6607107 Mouse anti-human CD45RO-BUV805 (clone: UCHL1) BD Biosciences cat# 748367; RRID: AB_2872786 Mouse anti-human IFN-g-BV786 (clone: 4S.B3) BioLegend cat# 502542; RRID: AB_2563882 Mouse anti-human TNF-BV650 (clone: MAb11) BioLegend cat# 502938; RRID: AB_2562741 Rat anti-human IL-13-BV421 (clone: JES10-5A2) BD Biosciences cat# 563580; RRID: AB_2738290 Mouse anti-human IL-21-Ax647 (clone: 3A3-N21) BD Biosciences cat# 560493; RRID: AB_1645421 Mouse anti-human IL-4-PE-Cy7 (clone:8D4-8) BD Biosciences cat# 560672; RRID: AB_1727547 Mouse anti-human IL-17A-BV605 (clone: BL168) BioLegend cat# 512326; RRID: AB_2563887 Rat anti-human IL-2-BUV737 (clone: MQ117H12) BD Biosciences cat# 612836 Mouse anti-human CD107A-BV711 (clone: H4A3) BioLegend cat# 328640; RRID: AB_2565840 Mouse anti-human MIP1b-Alexa700 (clone: D21-1351) BD Biosciences cat# 561278; RRID: AB_10612008 Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG1 (AS35) ACROBiosystems cat# SAD-S35 Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG2 (AS35) ACROBiosystems cat# SAD-S66 Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG3 (AS35) ACROBiosystems cat# SAD-S67 Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Human IgG4 (AS35) ACROBiosystems cat# SAD-S68 Mouse anti-Human IgG1 Fc Secondary Antibody, HRP Thermo Fisher Scientific cat# MH1715; RRID: AB_2539710 Mouse Anti-Human IgG2 Fc-BIOT HP6002 SouthernBiotech cat# 9070-08; RRID: AB_2796638 Mouse Anti-Human IgG3 Hinge-BIOT HP6050 SouthernBiotech cat# 9210-08; RRID: AB_2796700 Mouse Anti-Human IgG4 Fc-BIOT HP6025 SouthernBiotech cat# 9200-08; RRID: AB_2796692 Biological samples Human PBMCs This study This study Chemicals, peptides, and recombinant proteins Benzonase Nuclease, Purity >90% MERCK Millipore cat# 70746 (Continued on next page) Cell Reports Medicine 4, 101134, August 15, 2023 e1

Techniques: Injection

Journal: Angewandte Chemie International Edition

Article Title: Synthetic Homogeneous Glycoforms of the SARS‐CoV‐2 Spike Receptor‐Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies

doi: 10.1002/anie.202100543

Figure Lengend Snippet: Figure 4. Binding kinetics of RBDs to ACE2 and mAbs. A) Synthetic RBDs recognize ACE2 with similar affinity to wt-RBD. B) The binding profile between RBDs and mAb S309. C) The binding profile between RBDs and mAb CB6. D) The binding profile between RBDs and mAb AS35 (ACROBiosystems, anti-SARS-CoV-2 spike RBD neutralizing antibody, Human IgG1, cat. no. SAD-S35). wt-RBD: ACROBiosystems, Arg319-Lys537 with His Tag, cat. no. SPD-C52H1. ACE2: ACROBiosystems, cat. no. AC2-H5257.

Article Snippet: D) The binding profile between RBDs and mAb AS35 (ACROBiosystems, anti-SARS-CoV-2 spike RBD neutralizing antibody, Human IgG1, cat. no. SAD-S35). wt-RBD: ACROBiosystems, Arg319-Lys537 with His Tag, cat. no. SPD-C52H1.

Techniques: Binding Assay